Search This Blog

Thursday, November 7, 2019

Teva launches Rituxan biosimilar in U.S.

Teva Pharmaceutical Industries (NYSE:TEVA) and commercialization partner Celltrion announce the availability of Truxima (rituximab-abbs), a biosimilar to Roche’s (OTCQX:RHHBY) Rituxan, in the U.S.
The Wholesale Acquisition Cost (WAC) will be 10% lower than Rituxan at $845.55/100 mg vial and $4,227.75/500 mg vial. Actual costs should be lower since WAC does not account for additional rebates and discounts.
TEVA is up 4% premarket after posting Q3 results.
Posted by at No comments:

Achillion Pharmaceuticals EPS beats by $0.02

Achillion Pharmaceuticals (NASDAQ:ACHN): Q3 GAAP EPS of -$0.14 beats by $0.02.
Cash & equivalents of $229M.
The company’s acquisition by Alexion is expected to close by 1H20.
Press Release
Posted by at No comments:

Pacira Pharmaceuticals EPS beats by $0.16, misses on revenue

Pacira Pharmaceuticals (NASDAQ:PCRX): Q3 Non-GAAP EPS of $0.48 beats by $0.16; GAAP EPS of -$0.15 misses by $0.20.
Revenue of $104.7M (+25.5% Y/Y) misses by $0.18M.
Press Release
Posted by at No comments:

U.S. Physical Therapy EPS in-line, misses on revenue

U.S. Physical Therapy (NYSE:USPH): Q3 Non-GAAP EPS of $0.71 in-line; GAAP EPS of $0.66 misses by $0.05.
Revenue of $117.25M (+3.7% Y/Y) misses by $4.03M.
Press Release
Posted by at No comments:

MeiraGTx EPS beats by $0.23

MeiraGTx (NASDAQ:MGTX): Q3 Non-GAAP EPS of -$0.30 beats by $0.23.
License revenue of $3.58M
Press Release
Posted by at No comments:

Progenics Pharmaceuticals EPS beats by $0.04, misses on revenue

Progenics Pharmaceuticals (NASDAQ:PGNX): Q3 GAAP EPS of -$0.22 beats by $0.04.
Revenue of $5.61M (+5.5% Y/Y) misses by $1.8M.
Press Release
Posted by at No comments:

Cardinal Health EPS beats by $0.18, beats on revenue

Cardinal Health (NYSE:CAH): Q1 Non-GAAP EPS of $1.27 beats by $0.18; GAAP EPS of -$16.65.
Revenue of $37.34B (+6.0% Y/Y) beats by $590M.
Shares +0.27% PM.
Press Release
Posted by at No comments:
Subscribe to: Comments (Atom)